Skip to main content
. Author manuscript; available in PMC: 2015 Feb 2.
Published in final edited form as: Diagn Cytopathol. 2014 Apr;42(4):351–362. doi: 10.1002/dc.23093

Table III.

Proposed Ancillary Tests for Solid Pancreatic Lesions

Marker Purpose Diagnostic finding Utility
KRAS mutations Identification of adenocarcinoma Mutation present Insufficient specificity for malignancy to warrant usage
SMAD4 Identification of adenocarcinoma Mutation present [IHC shows loss of staining] Supports the diagnosis of adenocarcinoma
FISH Identification of adenocarcinoma Presence of copy number abnormalities in CEP3, CEP7, CEP17 and abnormalities of band 9p21 favor malignancy Most reliable test for confirming adenocarcinoma in conjunction with routine cytology
Mesothelin Identification of malignancy Overexpression of mesothelin by IHC Supports the diagnosis of adenocarcinoma
Loss of heterozygosity Identification of adenocarcinoma Losses of chromosome arms 3p, 6Qp and 10pq along with gains of 5q, 12q, 18q, and 20q supports a diagnosis adenocarcinoma Clinical importance to be determined
microRNAs Identification of adenocarcinoma Presence of miRNA including miR-21 and mi-155 supports a diagnosis of adenocarcinoma Clinical utility to be determined